Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
5.50
+0.01 (0.18%)
At close: Oct 24, 2025, 4:00 PM EDT
5.50
0.00 (0.01%)
After-hours: Oct 24, 2025, 7:58 PM EDT
Vanda Pharmaceuticals Revenue
Vanda Pharmaceuticals had revenue of $52.59M in the quarter ending June 30, 2025, with 4.19% growth. This brings the company's revenue in the last twelve months to $203.47M, up 11.78% year-over-year. In the year 2024, Vanda Pharmaceuticals had annual revenue of $198.77M with 3.18% growth.
Revenue (ttm)
$203.47M
Revenue Growth
+11.78%
P/S Ratio
1.58
Revenue / Employee
$552,899
Employees
368
Market Cap
324.99M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 198.77M | 6.13M | 3.18% |
| Dec 31, 2023 | 192.64M | -61.74M | -24.27% |
| Dec 31, 2022 | 254.38M | -14.30M | -5.32% |
| Dec 31, 2021 | 268.68M | 20.51M | 8.27% |
| Dec 31, 2020 | 248.17M | 20.98M | 9.23% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
VNDA News
- 4 days ago - Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025 - PRNewsWire
- 18 days ago - Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena - PRNewsWire
- 25 days ago - Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration - PRNewsWire
- 4 weeks ago - Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial" - PRNewsWire
- 2 months ago - Vanda: Next Phase Of Fanapt Growth Might Be With Bysanti Advancement - Seeking Alpha
- 2 months ago - Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences - PRNewsWire
- 2 months ago - Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera - PRNewsWire
- 2 months ago - Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz® - PRNewsWire